Abstract
IntroductionMultiple automated insulin delivery (AID) systems have become commercially available following randomised controlled trials demonstrating benefits in people with type 1 diabetes (T1D). However, their real-world utility may be undermined...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have